The influence of mifepristone to caspase 3 expression in adenomyosis.
OBJECTIVE
To discuss the influence of mifepristone to caspase 3 expression in adenomyosis tissue.


METHODS
Sixty patients were equally divided into four groups. Groups 1, 2, and 3 were treated with 5, 10, and 15 mg mifepristone, respectively and group 4 was treated with placebo. The expression of caspase 3 was examined by immunohistochemical method in both eutopic and ectopic endometria of the 40 cases.


RESULTS
Compared with placebo group, the expression of caspase 3 in both eutopic endometrium and ectopic endometrium in the three treatment groups was significantly increased. There was no difference in the expression of caspase 3 in both eutopic and ectopic endometria between the ten and 25 mg treatment groups, while both the ten and 25 mg treatment groups had a higher expression intensity of caspase 3 in both eutopic and ectopic endometria, compared with the five mg treatment group (p < 0.01).


CONCLUSIONS
Mifepristone can increase the expression of caspase 3 in both eutopic and ectopic endometria and initiate cell apoptosis in both eutopic and ectopic endometria. Therefore mifepristone can effectively inhibit the emergence and development of adenomyosis.
Y
Y
Wang
X
X
Jiang
S
S
Wang
D062788:Adenomyosis / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D053148:Caspase 3 / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004717:Endometrium / Q000378:metabolism*; D005260:Female; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015735:Mifepristone / Q000008:administration & dosage*
D006727:Hormone Antagonists; D015735:Mifepristone; D053148:Caspase 3